合并症与中轴型脊柱关节炎疾病活动度的关联:BSRBR-AS 研究结果
基于英国风湿病学会 AS 生物制剂注册登记(BSRBR-AS)2043 例基线数据,分析 14 种医生诊断合并症与疾病活动度指标的关系。每增加一种合并症,BASDAI 升高 0.40 单位(95%CI:0.27,0.52),脊柱疼痛升高 0.53(95%CI:0.37,0.68),ASDAS 升高 0.09 单位(95%CI:0.03,0.15)但无临床意义,ESR 和 CRP 与合并症数量无关。患者总体评分与合并症数量相关,但校正其他 ASDAS 组分后不独立相关(P=0.75)。
要点
- 合并症增加与 axSpA 患者报告的 BASDAI 和脊柱疼痛升高相关。
- ASDAS 受合并症影响较小,效应量未达临床显著。
- 合并症存在时应考虑补充采集 ASDAS 以辅助疾病活动度评估。
核心结论
- 合并症与 axSpA 患者报告疾病活动度升高相关,但对 ASDAS 影响无临床意义。
研究设计与样本
- 基于英国风湿病学会 AS 生物制剂注册登记(BSRBR-AS)基线数据的横断面分析,纳入 2043 例参与者(67% 男性,平均年龄 49 岁),包括 14 种医生诊断合并症,采用线性模型校正年龄、性别、BMI、吸烟、社会经济状况和教育水平。
主要发现
- 44% 的参与者至少有一种合并症。
- 每增加一种合并症,BASDAI 升高 0.40 单位(95%CI:0.27,0.52),脊柱疼痛升高 0.53(95%CI:0.37,0.68)。
- ASDAS 效应量为 0.09 单位(95%CI:0.03,0.15),未达临床显著。
- ESR 和 CRP 与合并症数量无关。
- 抑郁、心力衰竭和消化性溃疡与较高的疾病活动度指标一致相关,但与 CRP/ESR 无关。
关键数值与推荐
- 患者总体评分与合并症数量相关,但校正其他 ASDAS 组分后不独立相关(P=0.75)。
临床怎么用
- 临床医生应关注合并症对患者报告结局指标的潜在影响,合并症存在时考虑补充采集 ASDAS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether comorbidities influence disease activity assessment in axial SpA (axSpA) is unclear. Comorbidities inflate DAS28 in rheumatoid arthritis through the patient global score. We examined whether axSpA disease activity measures are differentially affected, and whether comorbidities inflate the AS disease activity score (ASDAS) through the patient global component. METHODS: We used baseline data from the British Society for Rheumatology Biologics Register for AS, including 14 physician diagnosed comorbidities. Linear models were used to compare disease activity (BASDAI, spinal pain, ASDAS) and ESR/CRP according to comorbidity count, adjusted for age, gender, BMI, smoking, socioeconomic status, and education. The same models were used to examine whether the patient global score was associated with comorbidities, additionally adjusting for other ASDAS components. RESULTS: The number of participants eligible for analysis was 2043 (67% male, mean age 49 years); 44% had at least one comorbidity. Each additional comorbidity was associated with higher BASDAI by 0.40 units (95% CI: 0.27, 0.52) and spinal pain by 0.53 (95% CI: 0.37, 0.68). Effect size for ASDAS (0.09 units; 95% CI: 0.03, 0.15) was not clinically significant. ESR and CRP were not associated with comorbidity count. Depression, heart failure and peptic ulcer were consistently associated with higher disease activity measures, but not CRP/ESR. Patient global was associated with comorbidity count, but not independently of other ASDAS components (P = 0.75). CONCLUSION: Comorbidities were associated with higher patient reported disease activity in axSpA. Clinicians should be mindful of the potential impact of comorbidities on patient reported outcome measures and consider additionally collecting ASDAS when comorbidities are present.
引用
- Zhao SS, Jones GT, Macfarlane GJ, et al. Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology (Oxford). 2021. PMID: 33331904. doi:10.1093/rheumatology/keaa768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。